Genetic testing company Natera (NASDAQ:NTRA). beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 34.7% year on year to $592.2 million. The company’s full-year revenue guidance of $2.22 billion at the midpoint came in 6.1% above analysts’ estimates. Its GAAP loss of $0.64 per share was 74.5% below analysts’ consensus estimates.
Natera (NTRA) Q3 2025 results beat revenue forecasts with $592.2M, driven by strong oncology test growth. The company raised its full-year 2025 guidance.
Genetic testing company Natera (NASDAQ:NTRA). reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 34.7% year on year to $592.2 million. The company’s full-year revenue guidance of $2.22 billion at the midpoint came in 6.1% above analysts’ estimates. Its GAAP loss of $0.64 per share was 74.5% below analysts’ consensus estimates.
Wall Street’s bearish price targets for the stocks in this article signal serious concerns.
Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Natera (NASDAQ:NTRA) and its peers.
Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 7.2% in the afternoon session after the company announced promising results from its phase 3 IMvigor011 clinical trial for its Signatera test.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 4.5% in the afternoon session after Wells Fargo & Company initiated coverage on the stock with a neutral "equal weight" rating and set a price target of $175.
Unprofitable companies face headwinds as they struggle to keep operating expenses under control.
Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 2.7% in the afternoon session after the company reached an $8.25 million settlement in a legal case. The case, titled 'Amanda Davis v. Natera Inc.,' was reported by the Daily Journal. While the financial impact of the settlement may not be substantial for a company of Natera's scale, news of legal disputes can create uncertainty among investors. The announcement may have raised concerns regarding the underlying issues of the lawsuit or the potential for future legal challenges, prompting a sell-off in the company's shares.
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 4.1% in the afternoon session after a key competitor, Exact Sciences, announced the launch of a new multi-cancer early detection blood test.
Since September 2020, the S&P 500 has delivered a total return of 94.8%. But one standout stock has doubled the market - over the past five years, Natera has surged 186% to $176.64 per share. Its momentum hasn’t stopped as it’s also gained 33.2% in the last six months thanks to its solid quarterly results, beating the S&P by 17.2%.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 0.9% in the morning session after the company announced an unfavorable court ruling in its ongoing patent litigation with competitor NeoGenomics.
NeoGenomics wins a North Carolina court ruling invalidating key Natera patents, clearing the way for its RaDaR ST assay and boosting investor sentiment.
